10 physicians win NCI Cancer Clinical Investigator Team Leadership Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ten investigators nationwide received the NCI’s Cancer Clinical Investigator Team Leadership Awards.

The award recognizes and supports outstanding clinical investigators at NCI-designated cancer centers who participate extensively in institute-funded collaborative clinical trials and whose leadership, participation, and activities promote a culture of successful clinical research.

Established in 2009, the awards are intended to help retain investigators in academic clinical research careers. Each of these investigators is a full-time faculty member who is a board-certified physician and has practiced medicine between three and eight years post-fellowship.

Each recipient was nominated for the award by their cancer center director on the basis of qualifications, interests, accomplishments, and motivation, and based upon the nominee’s intent and ability to promote a successful clinical trials culture and to pursue an academic career in clinical research.

The recipients will devote 15 to 20 percent effort to the activities associated with this award, and the sponsoring cancer centers have agreed to protect the awardees’ time for these activities. The award provides partial salary support for two years for the recipient to engage in activities and efforts related to the award.

The recipients for 2017 are:

Ajjai Alva
University of Michigan Comprehensive Cancer Center
Lisa Barroilhet
University of Wisconsin Carbone Cancer Center
Ursa Brown-Glaberman
University of New Mexico Comprehensive Cancer Center
Shira Dinner
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Jean Hoffman-Censits
Sidney Kimmel Cancer Center, Thomas Jefferson University
Kevin Kalinsky
Herbert Irving Comprehensive Cancer Center, Columbia University
Christopher Lieu
University of Colorado Comprehensive Cancer Center
Rahul Parikh
University of Pittsburgh Cancer Institute
Eric Roeland
Moores Comprehensive Cancer Center, University of California, San Diego
April Salama
Duke Cancer Institute, Duke University Medical Center

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login